Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. (ECILC.IS)
Istanbul, TR
EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a Turkish enterprise, operating predominantly in the health and real estate development sectors through its various subsidiaries. Its Health division is responsible for the production and distribution of pharmaceutical goods for both human and veterinary applications. Concurrently, the Real Estate Development segment is engaged in property creation and offers consultancy pertaining to land development and project oversight. This company, established in Istanbul, Turkey, in 1951, functions as a subsidiary of Eczacibasi Holding A.S.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.38% | -0.64% | -22.33% | -31.12% | +2.69% | +4.83% | +72.54% | +218.77% | +1,231.52% | +3,414.34% | +2,685,108.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+12.6% ★ Q1'26: +29.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+104.7% ★ Q1'26: -160.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-8.2% Q1'26: -4.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%-4.3% Q1'26: -9.0% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%-0.5% Q1'26: -1.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×6.21× ★ Q1'26: -16.87× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 2/5 | 5/5 | 2/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Turkey ETF TUR | 0.33% | 678.8K | 0.59% |
| 2 | JPMorgan Diversified Return Emerging Markets Equity ETF JPEM | 0.05% | 209.6K | 0.44% |
| 3 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.02% | 25.9K | 0.42% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.02% | 57.1K | 0.74% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.01% | 52.7K | 0.72% |
| 6 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.7K | 0.15% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.01% | 49.1K | 0.55% |
| 8 | Avantis Emerging Markets ex-China Equity ETF AVXC | 0.00% | 12.1K | 0.33% |
| 9 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.00% | 6.1K | 0.07% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 147.0K | 0.17% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Emin Fadillioglu | General Manager & Director | — | male |
| Erdal Osman Karamercan | President and Chief Executive Officer of Eczacibai Holding AS | — | — |
| Levent Avni Ersalman | President of Strategic Planning and Financing Group | — | male |
| Mustafa Sacit Basmaci | President of Financial Affairs Group | — | male |
| Rahmi Faruk Bulent Eczacibasi | Vice Chairman & Deputy Chief Executive Officer | — | male |
| Tugce Fatwaci | Investor Relations Manager & Director | — | — |
| Ülkü Feyyaz Taktak | Vice President of Human Resources | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ECILC.IS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
